ClinicalTrials.gg
TerminatedNCT05689164Updated Nov 12, 2026Results posted

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

A Phase 3 interventional study of fordadistrogene movaparvovec in Duchenne Muscular Dystrophy, sponsored by Pfizer. Terminated at 12 sites in United States. Open to male participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pfizer · Phase 3, Interventional, and Other

How we know

Why this study was terminated
All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003
Updated Nov 12, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
0 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
144th of 172
7 · median 25
Started
2023
with 5 others
Phase 3
32 of 233
3 open now
Registered
191st of 233
by date
Lead sponsor
7 of 233
Pfizer

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 144th largest by enrollment of the 172 interventional ones that give a count, is one of 6 that started in 2023, is one of 32 in phase 3, and was the 191st registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 0 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
  • Muscular Dystrophy, Duchenne
  • Genetic Therapy
  • Gene Therapy
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who received fordadistrogene movaparvovec in a previous Pfizer interventional study.

Exclusion criteria

Exclusion Criteria:

  • Investigator site staff directly involved in the study and their family members
05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Other
    All participants

    All participants enrolled in the study.

    Biological: fordadistrogene movaparvovec

Interventions

  • Biologicalfordadistrogene movaparvovec

    gene therapy administered in a previous study.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)

    An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related injury. All adverse events (AEs) were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing.

    Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  2. Number of Participants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of product under study, whether or not considered related to the product under study. AEs included SAEs and all non-SAEs. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related Injury. All AEs were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing. A treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. Relatedness to study intervention was assessed by investigator.

    Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  3. Number of Participants With Clinically Significant Abnormalities in Cardiac Troponin I

    Number of participants with clinically significant abnormalities in cardiac troponin I were reported in this outcome measure. Clinical significance of cardiac troponin I abnormalities was determined by the investigator.

    Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  4. Number of Participants With Clinically Significant Abnormalities in Echocardiogram Parameters

    Echocardiogram was performed using a 2-dimensional (2-D) imaging collection method and the parameters evaluated included left ventricular ejection fraction (LVEF). Clinical significance of abnormalities in echocardiogram parameters was determined by the investigator.

    Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  5. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters

    Standard 12-lead ECGs were performed using an ECG machine that automatically calculated the heart rate (HR) and measured PR interval, QT interval, QT interval corrected by Fridericia's formula (QTcF) and QRS complex after the participant had rested quietly for at least 10 minutes in a supine or sitting position. Clinical significance of ECG parameters was determined by the investigator.

    Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  6. Number of Participants With Malignancy Events

    Number of participants with malignancy events as collected on the case report form (CRF) were reported in this outcome measure.

    Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

Secondary outcomes

  1. Number of Participants With Non-Ambulatory Status at Baseline, Year 1 and Year 2

    Number of participants with non-ambulatory status at Baseline, Year 1 and Year 2 were reported in this outcome measure. Participants were asked to walk 10 meters unassisted. Participants who were unable to walk 10 meters unassisted were considered as non-ambulatory.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2

  2. Time to Loss of Ambulation

    Time to loss of ambulation was defined as the time from pre-fordadistrogene movaparvovec dosing in parent study to loss of participant's ability to walk 10 meters unassisted. Kaplan-Meier method was used.

    Time frame: From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)

  3. Number of Participants Who Were Unable to Climb Stairs at Baseline, Year 1 and Year 2

    Participants were asked if they were able to climb 1 flight of stairs. Investigator staff entered "Yes" or "No" depending on the participant's response. Number of participants who were unable to climb stairs (i.e., responded as No) at Baseline, Year 1 and Year 2 were reported in this outcome measure.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2

  4. Time to Loss of Ability to Climb Stairs

    Time to loss of ability of participant to climb 1 flight of stairs is reported in this outcome measure. Kaplan-Meier method was used.

    Time frame: From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)

  5. Change From Pre-Fordadistrogene Movaparvovec Administration in Performance of the Upper Limb (PUL) 2.0 Entry Score at Baseline, Year 1 and Year 2

    PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  6. Change From Baseline in PUL 2.0 Entry Score at Year 1 and Year 2

    PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  7. Change From Pre-Fordadistrogene Movaparvovec Administration in North Star Ambulatory Assessment (NSAA) Total Score at Baseline, Year 1 and Year 2

    The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  8. Change From Baseline in NSAA Total Score at Year 1 and Year 2

    The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  9. Change From Pre-Fordadistrogene Movaparvovec Administration in Percent (%) Predicted Forced Vital Capacity (pFVC) at Baseline, Year 1 and Year 2

    Forced vital capacity (FVC) was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  10. Change From Baseline in %pFVC at Year 1 and Year 2

    FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  11. Change From Pre-Fordadistrogene Movaparvovec Administration in %Predicted Peak Expiratory Flow (pPEF) at Baseline, Year 1 and Year 2

    PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  12. Change From Baseline in %pPEF at Year 1 and Year 2

    PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  13. Change From Pre-Fordadistrogene Movaparvovec Administration in LVEF at Baseline, Year 1 and Year 2

    LVEF was evaluated using the echocardiogram. Change from pre-fordadistrogene movaparvovec administration in LVEF at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  14. Change From Baseline in LVEF at Year 1 and Year 2

    LVEF was evaluated using the echocardiogram. Change from Baseline in LVEF at Year 1 and Year 2 was reported in this outcome measure.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  15. Age of Participants When %pFVC is <30%

    FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.

    Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  16. Age of Participants at Loss of Ambulation

    Loss of ambulation was defined as the loss of participant's ability to walk 10 meters unassisted. Age of participants at loss of ambulation is reported in this outcome measure.

    Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  17. Age of Participants at the Time of Death

    Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  18. Number of Participants According to Cause of Death

    Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

  19. Change From Pre-Fordadistrogene Movaparvovec Administration in Glucocorticoid Dose at Baseline, Year 1 and Year 2

    Change from pre-fordadistrogene movaparvovec administration in dose of glucocorticoids including prednisone/ prednisolone, and deflazacort at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  20. Change From Pre-Fordadistrogene Movaparvovec Administration in Modified Pediatric Outcomes Data Collection Instrument (PODCI) Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)

    Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  21. Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)

    Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  22. Change From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)

    Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  23. Change From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)

    Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  24. Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)

    Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  25. Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)

    Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

  26. Change From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)

    Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  27. Change From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)

    Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

    Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2

  28. Change From Pre-Fordadistrogene Movaparvovec Administration in Upper Limb Function Patient Reported Outcome Measure (UL-PROM) at Baseline, Year 1 and Year 2

    The UL-PROM was developed based on Food and Drug Administration (FDA) guidelines to assess activities of daily living in DMD participants that could not be observed in a clinical setting. The 32-item questionnaire covered 4 domains: food, self-care, household and environment, and leisure and communication. There were 3 possible response options for each item: 2 =can do easily, 1=can do with difficulty, and 0=impossible without help. The UL-PROM total score was calculated as the sum of the individual item responses and ranged from 0 to 64, with higher scores indicating better function. The total score was standardized to a score range of 0 (low function) to 100 (high function) by multiplying by 100 and dividing by 64, where higher scores indicated better function. The UL-PROM had to be completed only by non-ambulatory participants as pre-specified in the protocol. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

    Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

07

Results

Posted Nov 12, 2026

Participant flow

A total of 7 participants were enrolled in this long-term follow-up study. The study was terminated to streamline the long term follow up for all participants after the development of fordadistrogene movaparvovec was discontinued due to lack of efficacy in the pivotal Phase 3 study C3391003 \[NCT04281485\].

Participant flow — Overall Study
MilestoneAll Participants
Started7
Completed0
Not completed7
Withdrew: Study terminated by sponsor6
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Serious Adverse Events (SAEs)

An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related injury. All adverse events (AEs) were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing.

Time frame:
From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)
ParticipantsAll Participants
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)3
PrimaryNumber of Participants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of product under study, whether or not considered related to the product under study. AEs included SAEs and all non-SAEs. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related Injury. All AEs were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing. A treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. Relatedness to study intervention was assessed by investigator.

Time frame:
From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAll Participants
Number of Participants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Cardiac Troponin I

Number of participants with clinically significant abnormalities in cardiac troponin I were reported in this outcome measure. Clinical significance of cardiac troponin I abnormalities was determined by the investigator.

Time frame:
From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Cardiac Troponin I
ParticipantsAll Participants
Number of Participants With Clinically Significant Abnormalities in Cardiac Troponin I0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Echocardiogram Parameters

Echocardiogram was performed using a 2-dimensional (2-D) imaging collection method and the parameters evaluated included left ventricular ejection fraction (LVEF). Clinical significance of abnormalities in echocardiogram parameters was determined by the investigator.

Time frame:
From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Echocardiogram Parameters
ParticipantsAll Participants
Number of Participants With Clinically Significant Abnormalities in Echocardiogram Parameters0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters

Standard 12-lead ECGs were performed using an ECG machine that automatically calculated the heart rate (HR) and measured PR interval, QT interval, QT interval corrected by Fridericia's formula (QTcF) and QRS complex after the participant had rested quietly for at least 10 minutes in a supine or sitting position. Clinical significance of ECG parameters was determined by the investigator.

Time frame:
From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters
ParticipantsAll Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters0
PrimaryNumber of Participants With Malignancy Events

Number of participants with malignancy events as collected on the case report form (CRF) were reported in this outcome measure.

Time frame:
From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Count of participants · Participants
Number of Participants With Malignancy Events
ParticipantsAll Participants
Number of Participants With Malignancy Events0
SecondaryNumber of Participants With Non-Ambulatory Status at Baseline, Year 1 and Year 2

Number of participants with non-ambulatory status at Baseline, Year 1 and Year 2 were reported in this outcome measure. Participants were asked to walk 10 meters unassisted. Participants who were unable to walk 10 meters unassisted were considered as non-ambulatory.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
Reported as:
Count of participants · Participants
Number of Participants With Non-Ambulatory Status at Baseline, Year 1 and Year 2
ParticipantsAll Participants
Baseline3
Year 12
Year 20
SecondaryTime to Loss of Ambulation

Time to loss of ambulation was defined as the time from pre-fordadistrogene movaparvovec dosing in parent study to loss of participant's ability to walk 10 meters unassisted. Kaplan-Meier method was used.

Time frame:
From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
Reported as:
Median · Years
Time to Loss of Ambulation
YearsAll Participants
Time to Loss of AmbulationNA (3.91 to NA)
SecondaryNumber of Participants Who Were Unable to Climb Stairs at Baseline, Year 1 and Year 2

Participants were asked if they were able to climb 1 flight of stairs. Investigator staff entered "Yes" or "No" depending on the participant's response. Number of participants who were unable to climb stairs (i.e., responded as No) at Baseline, Year 1 and Year 2 were reported in this outcome measure.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
Reported as:
Count of participants · Participants
Number of Participants Who Were Unable to Climb Stairs at Baseline, Year 1 and Year 2
ParticipantsAll Participants
Baseline4
Year 12
Year 21
SecondaryTime to Loss of Ability to Climb Stairs

Time to loss of ability of participant to climb 1 flight of stairs is reported in this outcome measure. Kaplan-Meier method was used.

Time frame:
From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
Reported as:
Median · Years
Time to Loss of Ability to Climb Stairs
YearsAll Participants
Time to Loss of Ability to Climb Stairs4.97 (3.04 to NA)
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Performance of the Upper Limb (PUL) 2.0 Entry Score at Baseline, Year 1 and Year 2

PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Pre-Fordadistrogene Movaparvovec Administration in Performance of the Upper Limb (PUL) 2.0 Entry Score at Baseline, Year 1 and Year 2
Units on a scaleAll Participants
Baseline-0.8 ± 1.17
Year 1-0.8 ± 1.5
Year 20.0 ± 0.0
SecondaryChange From Baseline in PUL 2.0 Entry Score at Year 1 and Year 2

PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Baseline in PUL 2.0 Entry Score at Year 1 and Year 2
Units on a scaleAll Participants
Year 10.3 ± 0.5
Year 20.0 ± 0.0
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in North Star Ambulatory Assessment (NSAA) Total Score at Baseline, Year 1 and Year 2

The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Pre-Fordadistrogene Movaparvovec Administration in North Star Ambulatory Assessment (NSAA) Total Score at Baseline, Year 1 and Year 2
Units on a scaleAll Participants
Baseline-12.3 ± 11.7
Year 1-14.5 ± 4.95
Year 2-14.0 ± 7.07
SecondaryChange From Baseline in NSAA Total Score at Year 1 and Year 2

The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Baseline in NSAA Total Score at Year 1 and Year 2
Units on a scaleAll Participants
Year 1-6.0 ± 5.66
Year 2-5.5 ± 3.54
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Percent (%) Predicted Forced Vital Capacity (pFVC) at Baseline, Year 1 and Year 2

Forced vital capacity (FVC) was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Percentage of pFVC
Change From Pre-Fordadistrogene Movaparvovec Administration in Percent (%) Predicted Forced Vital Capacity (pFVC) at Baseline, Year 1 and Year 2
Percentage of pFVCAll Participants
Baseline-15.57 ± 25.973
Year 1-19.5 ± 28.314
Year 2-21.5 ± 31.82
SecondaryChange From Baseline in %pFVC at Year 1 and Year 2

FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Percentage of pFVC
Change From Baseline in %pFVC at Year 1 and Year 2
Percentage of pFVCAll Participants
Year 1-7.25 ± 7.136
Year 2-4.0 ± 12.728
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in %Predicted Peak Expiratory Flow (pPEF) at Baseline, Year 1 and Year 2

PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

No measurements were reported for this outcome.

SecondaryChange From Baseline in %pPEF at Year 1 and Year 2

PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Percentage of pPEF
Change From Baseline in %pPEF at Year 1 and Year 2
Percentage of pPEFAll Participants
Year 1-3.02 ± 12.584
Year 214.95 ± 17.324
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in LVEF at Baseline, Year 1 and Year 2

LVEF was evaluated using the echocardiogram. Change from pre-fordadistrogene movaparvovec administration in LVEF at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Percentage of ejected blood
Change From Pre-Fordadistrogene Movaparvovec Administration in LVEF at Baseline, Year 1 and Year 2
Percentage of ejected bloodAll Participants
Baseline-4.0 ± NA
SecondaryChange From Baseline in LVEF at Year 1 and Year 2

LVEF was evaluated using the echocardiogram. Change from Baseline in LVEF at Year 1 and Year 2 was reported in this outcome measure.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Percentage of ejected blood
Change From Baseline in LVEF at Year 1 and Year 2
Percentage of ejected bloodAll Participants
Year 1-1.0 ± 2.0
Year 2-16.0 ± NA
SecondaryAge of Participants When %pFVC is <30%

FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.

Time frame:
From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

No measurements were reported for this outcome.

SecondaryAge of Participants at Loss of Ambulation

Loss of ambulation was defined as the loss of participant's ability to walk 10 meters unassisted. Age of participants at loss of ambulation is reported in this outcome measure.

Time frame:
From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Reported as:
Mean · Years
Age of Participants at Loss of Ambulation
YearsAll Participants
Age of Participants at Loss of Ambulation14.3 ± 1.53
SecondaryAge of Participants at the Time of Death
Time frame:
From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

No measurements were reported for this outcome.

SecondaryNumber of Participants According to Cause of Death
Time frame:
From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)

No measurements were reported for this outcome.

SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Glucocorticoid Dose at Baseline, Year 1 and Year 2

Change from pre-fordadistrogene movaparvovec administration in dose of glucocorticoids including prednisone/ prednisolone, and deflazacort at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Milligrams per kilogram per day
Change From Pre-Fordadistrogene Movaparvovec Administration in Glucocorticoid Dose at Baseline, Year 1 and Year 2
Milligrams per kilogram per dayAll Participants
Baseline: Prednisone/ Prednisolone-0.06 ± 0.0966
Year 1: Prednisone/ Prednisolone-0.161 ± NA
Baseline: Deflazacort-0.194 ± 0.3467
Year 1: Deflazacort0.079 ± 0.2057
Year 2: Deflazacort-0.022 ± NA
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Modified Pediatric Outcomes Data Collection Instrument (PODCI) Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)

Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified Pediatric Outcomes Data Collection Instrument (PODCI) Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)
Units on a scaleAll Participants
Baseline-31.78 ± 24.5405
Year 1-35.101 ± 20.7793
Year 2-46.97 ± 26.7843
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)

Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)
Units on a scaleAll Participants
Baseline-71.212 ± NA
Year 1-64.394 ± NA
SecondaryChange From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)

Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)
Units on a scaleAll Participants
Year 1-9.596 ± 5.0442
Year 2-30.682 ± 24.1059
SecondaryChange From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)

Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)
Units on a scaleAll Participants
Year 1-12.879 ± 25.5113
Year 2-9.091 ± 2.1427
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)

Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)
Units on a scaleAll Participants
Baseline-38.426 ± 23.1643
Year 1-28.914 ± 26.6057
Year 2-22.506 ± 28.3468
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)

Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)
Units on a scaleAll Participants
Baseline-51.288 ± NA
Year 1-44.697 ± NA
SecondaryChange From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)

Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)
Units on a scaleAll Participants
Year 10.189 ± 9.5531
Year 2-8.617 ± 13.6154
SecondaryChange From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)

Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.

Time frame:
Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Reported as:
Mean · Units on a scale
Change From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)
Units on a scaleAll Participants
Year 1-12.986 ± 6.58
Year 2-22.506 ± 3.0802
SecondaryChange From Pre-Fordadistrogene Movaparvovec Administration in Upper Limb Function Patient Reported Outcome Measure (UL-PROM) at Baseline, Year 1 and Year 2

The UL-PROM was developed based on Food and Drug Administration (FDA) guidelines to assess activities of daily living in DMD participants that could not be observed in a clinical setting. The 32-item questionnaire covered 4 domains: food, self-care, household and environment, and leisure and communication. There were 3 possible response options for each item: 2 =can do easily, 1=can do with difficulty, and 0=impossible without help. The UL-PROM total score was calculated as the sum of the individual item responses and ranged from 0 to 64, with higher scores indicating better function. The total score was standardized to a score range of 0 (low function) to 100 (high function) by multiplying by 100 and dividing by 64, where higher scores indicated better function. The UL-PROM had to be completed only by non-ambulatory participants as pre-specified in the protocol. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.

Time frame:
Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2

No measurements were reported for this outcome.

Adverse events

Collected over From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants0/7 (0%)3/7 (42.9%)4/7 (57.1%)
Most frequent serious events
Most frequent serious events
EventAll Participants
Cardiac failure congestiveCardiac disorders1/7
FallInjury, poisoning and procedural complications1/7
Femur fractureInjury, poisoning and procedural complications1/7
SchwannomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/7
Most frequent other events
Most frequent other events
EventAll Participants
InfluenzaInfections and infestations1/7
FallInjury, poisoning and procedural complications1/7
Pain in extremityMusculoskeletal and connective tissue disorders1/7
HypotensionVascular disorders1/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean13.4 ± 1.81
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female0
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
08

Study locations

12 sites
  • Reed Neurological Research Center
    Los Angeles, California 90095, United States
  • UCLA Children's Heart Center
    Los Angeles, California 90095, United States
  • UCLA Clinical Lab Services
    Los Angeles, California 90095, United States
  • UCLA Kameron Gait and Motion Analysis Laboratory (Westwood Rehabilitation Center)
    Los Angeles, California 90095, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Duke Lenox Baker Children's
    Durham, North Carolina 27705, United States
  • Duke Children's Health Center
    Durham, North Carolina 27710, United States
  • University of Utah Imaging and Neurosciences Center
    Salt Lake City, Utah 84108, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84112, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • University of Utah Clinical Neurosciences Center
    Salt Lake City, Utah 84132, United States
  • University of Utah Craig H. Neilsen Rehabilitation Hospital
    Salt Lake City, Utah 84132, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Sep 2025, 30 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Jan 19, 2023
StartActual
Mar 13, 2023
Primary completionActual
Sep 24, 2025
CompletionActual
Sep 24, 2025
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Primary outcomes
6 edited, 2 removed
What changed in the outcomes
  • EditedNumber of participants with serious adverse eventsParticipants With Treatment Emergent Serious Adverse Events (SAEs)Time frame: At least annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedPercentageNumber of participants with serious adverse eventsParticipants With Malignancy EventsTime frame: At least annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedNumber of participants with adverse events considered related to treatmentParticipants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)Time frame: At least annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedNumber of participants with clinically significant findingsParticipants With Clinically Significant Abnormalities in electrocardiogram (ECG) assessmentsCardiac Troponin ITime frame: Annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedNumber of participants with clinically significant findingsParticipants With Clinically Significant Abnormalities in cardiac troponin I laboratory examinationsEchocardiogram ParametersTime frame: Annually from 5 through 10 years after dosing in the interventional study → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedNumber of participants with clinically significant findingsParticipants With Clinically Significant Abnormalities in echocardiogram parametersElectrocardiogram (ECG) ParametersTime frame: Annually from 5 through 10 years after dosing in the interventional study → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • RemovedPercentage of particpants with adverse events considered related to treatmentTime frame: At least annually from 5 through 10 years after dosing in the interventional study
  • RemovedNumber of participants with malignancy adverse eventTime frame: At least annually from 5 through 10 years after dosing in the interventional study
Nov 12, 2026
Documents
Secondary outcomes
8 edited, 20 added, 2 removed, 3 more
What changed in the outcomes
  • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in the Performance of the Upper Limb (PUL) 2.0 entry scoreEntry Score at Baseline, Year 1 and Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in the North Star Ambulatory Assessment total score(NSAA) Total Score at Baseline, Year 1 and Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in percent of predicted forced vital capacityPercent (%) Predicted Forced Vital Capacity (pFVC) at Baseline, Year 1 and percent predicted peak expiratory flow (%pPEF)Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in the Upper Limb Function Patient Reported Outcome Measure (UL-PROM) at Baseline, Year 1 and Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • EditedAge when percent predicted forced vital capacityof Participants When %pFVC is <30%Time frame: Annually from 5 through 10 years after dosing in the interventional study → From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedAge at lossTime to Loss of ambulationAmbulationTime frame: From 5 through 10 years after dosing in the interventional study → From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
  • EditedAge of Participants at deaththe Time of DeathTime frame: From 5 through 10 years after dosing in the interventional study → From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • EditedNumber of Participants According to Cause of deathDeathTime frame: From 5 through 10 years after dosing in the interventional study → From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • AddedNumber of Participants With Non-Ambulatory Status at Baseline, Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
  • AddedNumber of Participants Who Were Unable to Climb Stairs at Baseline, Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
  • AddedTime to Loss of Ability to Climb StairsTime frame: From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
  • AddedChange From Baseline in PUL 2.0 Entry Score at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Baseline in NSAA Total Score at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Baseline in %pFVC at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in %Predicted Peak Expiratory Flow (pPEF) at Baseline, Year 1 and Year 2Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Baseline in %pPEF at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in LVEF at Baseline, Year 1 and Year 2Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Baseline in LVEF at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedAge of Participants at Loss of AmbulationTime frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Glucocorticoid Dose at Baseline, Year 1 and Year 2Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified Pediatric Outcomes Data Collection Instrument (PODCI) Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
  • AddedChange From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • AddedChange From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
  • RemovedChange from pre-dose in the ability to walk 10 meters unassistedTime frame: Annually from 5 through 10 years after dosing in the interventional study.
  • RemovedChange from pre-dose in the ability to climb stairs.Time frame: Annually from 5 through 10 years after dosing in the interventional study
  • …and 3 more, on the record history on ClinicalTrials.gov ↗
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Primary outcomes 6 edited, 2 removed
    What changed in the outcomes
    • EditedNumber of participants with serious adverse eventsParticipants With Treatment Emergent Serious Adverse Events (SAEs)Time frame: At least annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedPercentageNumber of participants with serious adverse eventsParticipants With Malignancy EventsTime frame: At least annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedNumber of participants with adverse events considered related to treatmentParticipants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)Time frame: At least annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedNumber of participants with clinically significant findingsParticipants With Clinically Significant Abnormalities in electrocardiogram (ECG) assessmentsCardiac Troponin ITime frame: Annually from 5 through 10 years after dosing in the interventional study. → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedNumber of participants with clinically significant findingsParticipants With Clinically Significant Abnormalities in cardiac troponin I laboratory examinationsEchocardiogram ParametersTime frame: Annually from 5 through 10 years after dosing in the interventional study → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedNumber of participants with clinically significant findingsParticipants With Clinically Significant Abnormalities in echocardiogram parametersElectrocardiogram (ECG) ParametersTime frame: Annually from 5 through 10 years after dosing in the interventional study → From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • RemovedPercentage of particpants with adverse events considered related to treatmentTime frame: At least annually from 5 through 10 years after dosing in the interventional study
    • RemovedNumber of participants with malignancy adverse eventTime frame: At least annually from 5 through 10 years after dosing in the interventional study
    Secondary outcomes 8 edited, 20 added, 2 removed, 3 more
    What changed in the outcomes
    • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in the Performance of the Upper Limb (PUL) 2.0 entry scoreEntry Score at Baseline, Year 1 and Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in the North Star Ambulatory Assessment total score(NSAA) Total Score at Baseline, Year 1 and Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in percent of predicted forced vital capacityPercent (%) Predicted Forced Vital Capacity (pFVC) at Baseline, Year 1 and percent predicted peak expiratory flow (%pPEF)Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • EditedChange from preFrom Pre-doseFordadistrogene Movaparvovec Administration in the Upper Limb Function Patient Reported Outcome Measure (UL-PROM) at Baseline, Year 1 and Year 2Time frame: Annually from 5 through 10 years after dosing in the interventional study → Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • EditedAge when percent predicted forced vital capacityof Participants When %pFVC is <30%Time frame: Annually from 5 through 10 years after dosing in the interventional study → From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedAge at lossTime to Loss of ambulationAmbulationTime frame: From 5 through 10 years after dosing in the interventional study → From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
    • EditedAge of Participants at deaththe Time of DeathTime frame: From 5 through 10 years after dosing in the interventional study → From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • EditedNumber of Participants According to Cause of deathDeathTime frame: From 5 through 10 years after dosing in the interventional study → From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • AddedNumber of Participants With Non-Ambulatory Status at Baseline, Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
    • AddedNumber of Participants Who Were Unable to Climb Stairs at Baseline, Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
    • AddedTime to Loss of Ability to Climb StairsTime frame: From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
    • AddedChange From Baseline in PUL 2.0 Entry Score at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Baseline in NSAA Total Score at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Baseline in %pFVC at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in %Predicted Peak Expiratory Flow (pPEF) at Baseline, Year 1 and Year 2Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Baseline in %pPEF at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in LVEF at Baseline, Year 1 and Year 2Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Baseline in LVEF at Year 1 and Year 2Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedAge of Participants at Loss of AmbulationTime frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Glucocorticoid Dose at Baseline, Year 1 and Year 2Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified Pediatric Outcomes Data Collection Instrument (PODCI) Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
    • AddedChange From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • AddedChange From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
    • RemovedChange from pre-dose in the ability to walk 10 meters unassistedTime frame: Annually from 5 through 10 years after dosing in the interventional study.
    • RemovedChange from pre-dose in the ability to climb stairs.Time frame: Annually from 5 through 10 years after dosing in the interventional study
    • …and 3 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05689164
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 19, 2023
Start date
Mar 13, 2023
Primary completion
Sep 24, 2025
Completion
Sep 24, 2025
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion